nextpoint therapeutics

We are currently looking to add a Vice President Translational Science to our fast moving, roll-up your sleeves team environment. By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. 25. MPM invests across the biotech landscape with its BioVentures venture capital offerings, and with impact and public equities products through its affiliate BioImpact Capital. Information, Analyst This laboratory-based role will work across our emerging portfolio to ensure the efficient execution of multiple therapeutic programs. any facility of a national securities exchange of the United States and the tender offer cannot be 2+ years experience managing direct reports including oversight of CRAs. 40789 Monheim am Rhein The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients, NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Cancer Immunol Res. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. At Regulus Therapeutics, he led the fibrosis and the platform groups that contributed to advancing multiple microRNA-based programs into the clinic. Please note that if you are visiting the Site from outside of the United States, your information may be transferred to, stored, and/or processed in the US. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. & Teamwork, Better offered or sold Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any Janakiram M, Chinai JM, Fineberg S, et al. Clin Cancer Res. Submit material that is intentionally false, defamatory, unlawfully threatening or unlawfully harassing. These factors include those discussed in Bayers public reports which are available on the Bayer website at www.bayer.com. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. language options. Stories, Annual Dr. Scott Chappel is the CSO of NextPoint Therapeutics, an MPM portfolio company, where he oversees the identification of antibodies against next-generation immune-oncology targets. 5. be made at any time under the following exemptions from the Prospectus Directive, if they have been NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Headquarters, Dominican Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. In other We may also use web beacons or pixels, and in certain circumstances may collect IP address, screen resolution and browser software and operating system types, clickstream patterns, dates and times that our site is accessed, and other categories of data. (888) 929-NEXT 4043 N Ravenswood Ave, #317, Chicago, 60613 hello@nextpoint.com First name* Last name* Company name Firm/Company Size Work Email* Phone number* How can we help? 50 The financing will be used to advance NextPoint . Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . Furthermore, where permissible, we may charge for this service. Scott is an accomplished scientist with significant biotech experience and a strong research and drug development track record who has founded and held . Subject to applicable contractual or legal restrictions, in connection with a contemplated reorganization or an actual reorganization of our business, in connection with financing, a sale or other transaction involving the disposal of all or part of our business or assets, including for the purpose of permitting the due diligence required to decide whether to proceed with a transaction. CAMBRIDGE, Mass. Cambridge, MA / Leverkusen, Germany, January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Management, Code of Conduct Use the Website in a manner that could disable, overburden or impair the Website or interfere with any other partys use and enjoyment of the Website, such as through sending spam.. for If you are located outside of the United States, the transfer of Personal Data is necessary to provide you with the requested information and Site and/or to perform any requested transaction. Reporting to the Chief Medical Officer, the Vice President will build our Translational Medicine capability, responsible for managing research activities bridging from discovery to clinical development. Deforestation and Forest Degradation, Postion OurPrivacy Noticeexplains how we treat information that you provide to us through the Website and our Terms govern your use of our Website and Content. requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. "We've been profitable and self-funded for 20 years. This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. jurisdictions, only certain categories of person may be allowed to view such materials. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Leaps by Bayer and Sanofi Ventures co-led the round and were joined . Drs. Report, Quarterly CAMBRIDGE, Mass. State. shall form the basis of, or be relied upon in connection with, any offer or commitment NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. As CMO, Dr. Gandhi will oversee the clinical development of NextPoints precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Find out more: www.sanofiventures.com, Find more information at https://pharma.bayer.com/, Follow us on Facebook: http://www.facebook.com/bayer. Governance, Sustainability Marketing & Sales, Group Bayer CapSeal App, Better Harvests I understand that it may affect my rights. Sanofi Ventures is the corporate venture capital arm of Sanofi. Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Reports, Bayer AG language options. These materials do not constitute or form a part of any offer or Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. 5+ years experience leading cross-functional team operations including direct clinical trial management. Health, Crop Leaps by Bayer and Sanofi Ventures led the round for the Cambridge, Massachusetts-based company. These electronic materials are thus extremely vulnerable to unauthorized distribution and copyright infringement. Some cookies and other technologies may serve to track Personal Data previously entered by a web user on our site. Please note, however, we cannot fully eliminate security risks associated with the storage and transmission of Personal Data. Education, Health, NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. China, United At the same time, the Group aims to increase its earning power and create value through innovation and growth. Council, Stakeholder Phone: Strategy, Bio Revolution The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as Our scientific successes are intended to help improve peoples lives. 2021 Feb;9(2):156-169. expression Prospectus Directive includes any relevant implementing measure in each Relevant Member the Market, Pharmaceutical The company assumes no liability whatsoever to update these forward-looking statements or to conform, Deutsch Global, Bayer NextPoint Therapeutics, Inc. Street Address 1 Street Address 2; 238 MAIN STREET: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02142: 5082041115: 3. Find out more: www.sanofiventures.com, Kira PeikoffLeaps by Bayer1(973)791-3348kira.peikoff@bayer.com. Authority, Saudi Stewardship, Pharmaceuticals Audit, International In other jurisdictions, only certain categories of person may be allowed to view such At the same time, the Group aims to increase its earning power and create value through innovation and growth. NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our. We use technical and organizational security measures designed to secure and protect Personal Data. States by use of the mails or by any means or instrumentality (including, without limitation, Sci Immunol. Sustainable Beef Production, Responsible Business The online community has not agreed on what actions, if any, should be taken by the websites that receive the do not track signal, and therefore Do-Not-Track is not yet standardized. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. This website is intended to provide information to an international audience outside the USA and UK. Fraudulent Brands, Commitment to States, Australia, Canada or Japan. Sustainable Development Goals, Position Feel free to contact me at Joash.tan.kiat@gmail.com or +65 97857618! Our team of . an offer to the public of the securities has not been made and will not be made in such Relevant Cambridge, MA / Leverkusen, Germany January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Use, Privacy made on the basis of the securities prospectus. & Rewards, Values We also use cookies and similar technologies for purposes of marketing and advertising. Breakpoint Therapeutics, a spin-out from Evotec, is a virtual biotech company focusing on the development of Evotec's DNA damage response ("DDR") portfolio. We'd love to talk to you. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by for "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. any jurisdiction. Publications, Job Our Site may contain links or otherwise provide access to another website, mobile application, or Internet location (collectively Third-Party Sites). Trends, Growing Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . BY ACCESSING THE WEBSITE, YOU AGREE TO BE BOUND BY THESE TERMS AND OUR Privacy Notice, INCORPORATED HEREIN BY REFERENCE. Associate Director, NextPoint Therapeutics, Boston, Massachusetts; Health Data Science Leader, Insight Data Science, San Francisco, California; Self-employed, Medical Writer and Editor at CRL MedWrite; Senior Regulatory Specialist at Enable Injections, Inc., Cincinnati, Ohio; Pharmacogenomics Project Manager, Vanderbilt University Medical Center Bayer Global NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. These factors include those discussed in Bayers public reports which are available on the Bayer website at, . However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. Distances, Work We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. Investing in a stronger future - for our shareholders, and for the world. NextPoint does not sell your Personal Information. Germany being referred to as relevant persons). Leena Gandhi, director of the Dana-Farber Cancer Institute's Center for Cancer Therapeutic Innovation and a 15-year veteran of the organization, has left to become chief medical officer of. IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS, PLEASE DO NOT ACCESS WEBSITE OR USE THE WEBSITE OR CONTENT. The securities are only available to, and any invitation, Bayer Global Archive, Events Management, Supervisory materials or any of their contents. Your computer and mobile devices when you visit our Site. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Meeting & Agenda, Stockholders' If you become aware that an individual under 13 years of age has provided us with Personal Data without parental consent, please contact us atinfo@nextpointtx.com. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs, LabCentral, 238 Main Street, 5th Floor, Cambridge, MA 02142. We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements. on Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Interview, Check Drs. NextPoint Therapeutics, founded and funded by MPM Capital, has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class #immunotherapies based on a novel,. Personal Information does not include publicly available information, information that is de-identified, aggregated information, or any other information outside the scope of the California Consumer Privacy Act of 2018 (CCPA). To assist you in using the Website, we have created (i) these Terms of Use (the Terms), and (ii) aPrivacy Notice. Announcements, Sustainability & For example, you will not use the Website to violate any law, statute or regulation (including, without limitation, those governing export control, consumer protection, unfair competition, anti-discrimination or false advertising). implemented in the Relevant Member State: provided that no such offer shall result in a requirement to publish a prospectus pursuant to They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. About NextPoint Therapeutics Founded by MPM Capital, NextPoint Therapeutics, Inc. has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies with the goal of delivering new options to people with cancer. e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of By clicking on the I AGREE button, I certify that I am not located solutions The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. Phone: NextPoint Therapeutics Raises $80M in Series B Financing | Precision Oncology News The firm plans to put the funds toward its investigational immunotherapies targeting HHLA2 on difficult-to-treat, PD-L1-negative cancers. Copyright and Legal Notice. Oricell has applied for over 100 invention patents (including 6 PCT), with 10 already granted. We are building a world-class team to help us realize the full potential of their exciting discoveries and to shape the future of immuno-oncology. Transmit materials that contain any viruses, Trojan horses, worms, time bombs, cancelbots or other computer-programming routines that are intended to damage, detrimentally interfere with, surreptitiously intercept or expropriate any system, data or personal information. This announcement is an advertisement and does not, under any circumstances, constitute a public Neither this announcement nor anything contained Detlev is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role. Demand, Breakthroughs Republic of, New for or the solicitation of an offer to buy or subscribe for, any securities.

36 Caliber Black Powder Revolver Made In Italy, Newark, Ohio Busted Mugshots, Vincennes Community School Corporation Calendar, Atlas Geoportal Maps Hancock County Ms, Articles N